Every 8-K that Medicus Pharma Ltd. Warrant (MDCXW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MDCXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCXW filings page.
Medicus Pharma Ltd. effected a 1-for-50 consolidation of its issued and outstanding common shares, effective October 12, 2026; the shares began trading on a post-consolidation basis on the Nasdaq Capital Market that day. Every 50 common shares were automatically consolidated into one new common share. Shareholders approved a consolidation of up to 1-for-50 on June 3, 2026, and the board approved the 1-for-50 ratio on September 24, 2026.
The consolidation did not modify common-share rights or preferences. Proportionate adjustments were made to exercise or conversion prices and share counts for outstanding equity awards, convertible securities, warrants and equity incentive plans. Fractional shares were rounded down, with cash paid in lieu.
Medicus Pharma Ltd. will effect a 50-to-1 consolidation of its common shares effective October 12, 2026. Trading on a consolidated basis is expected to begin at the commencement of trading on October 12, 2026.
Every 50 issued and outstanding common shares will be exchanged for one new common share. No fractional shares will be issued; holdings that would otherwise produce a fraction will be rounded down to the next whole share, with cash paid in lieu. Voting power and share rights will remain unchanged. Proportionate adjustments will be made to exercise prices and shares issuable upon exercise or conversion of outstanding equity awards, convertible securities and warrants, and to shares under equity incentive plans. The company name and MDCX ticker will remain unchanged.
Medicus Pharma Ltd. (MDCX) reports that on September 11, 2026 it and YA II PN, Ltd. mutually agreed to terminate their Standby Equity Purchase Agreement (SEPA), which had allowed the company to issue and sell up to $15.0 million of common shares. At termination, there were no outstanding borrowings, advance notices, or common shares to be issued under the SEPA, and no fees are due by either party in connection with the termination. Yorkville Securities, LLC, an affiliate of YA II PN, Ltd., remains a sales agent under Medicus Pharma’s Equity Distribution Agreement dated December 29, 2025, as amended.
Medicus Pharma Ltd. (MDCX) reported that on September 4, 2026 it granted an aggregate of 8,529,412 restricted common shares to certain officers and employees who elected to forgo cash bonuses. These shares represent the value of approximately $1.45 million of cash bonuses, converted at $0.1705 per share, the Nasdaq Capital Market closing price on September 3, 2026.
No additional cash consideration changed hands in this issuance, which was made as a private offering exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Medicus Pharma Ltd. (MDCX) entered into a Co-Development and License Agreement with Pfizer Inc. for PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate targeting melanotransferrin (CD228). Medicus receives an exclusive, sublicensable, worldwide license to develop, manufacture and commercialize CD228V and related products for all human diseases.
As consideration, Medicus paid Pfizer a $12.0 million non-refundable upfront payment and must pay an additional $15.0 million on the first anniversary of the effective date. Pfizer paid Medicus a $2.0 million non-refundable Development Funding Payment to be used solely for CD228V development activities. Pfizer is eligible for development, regulatory and sales-based milestone payments that in aggregate exceed $1.0 billion, plus tiered low double-digit royalties on annual Net Sales.
Medicus retains sole authority and bears the costs for development, regulatory approval, manufacturing and commercialization, while Pfizer keeps ownership of the patent rights and an economic interest via milestones, royalties and specified participation in change-of-control, sublicensing or other strategic transactions. Pfizer also holds an option to fund all or part of development from and after the first pivotal trial, subject to a separate definitive agreement.
Medicus Pharma Ltd. held its 2026 Annual General and Special Meeting of Shareholders on June 3, 2026. Shareholders ratified the appointment of KPMG LLP as independent auditor for the 2026 fiscal year, with 28,308,860 votes for and 756,378 votes withheld.
All nine director nominees were elected, each receiving about 15.1 million votes for and 13.5 million broker non-votes. Shareholders also approved a special resolution authorizing the board to implement a consolidation of the company’s common shares at a ratio of up to 50 pre-consolidation shares for each post-consolidation share, if the board determines such a step is necessary or desirable.
Medicus Pharma Ltd. entered into a secured note financing totaling $12,864,225 and $10,000,000 and disclosed noncompliance with Nasdaq’s market value listing standard.
The company issued a Secured Promissory Note A-1 with an 8.75% interest rate, an original issue discount of $834,225, and received $12,000,000 in cash with about $2,500,000 used to repay an existing debenture. A separate B Note of $10,000,000 at 5% interest was funded into a controlled deposit account and can be exchanged into A-type notes, releasing cash as redemptions occur. Both notes mature in 18 months and carry prepayment premiums of 110% or 115%, monthly and trading-based redemption features, and event-driven balance step-ups.
Nasdaq notified the company that its Market Value of Listed Securities has been below $35,000,000 for 30 consecutive business days and that it also fails alternative equity and income standards. Medicus has 180 days, until November 16, 2026, to regain compliance or face potential delisting, though its shares and warrants continue trading under “MDCX” and “MDCXW.”
Medicus Pharma Ltd. amended its Equity Distribution Agreement with Maxim Group and Yorkville Securities to expand its at-the-market stock sales program from $15,349,674 to up to $50,000,000. The company has already raised about $11.5 million under this program.
Medicus also received a Nasdaq notice that its shares traded below $1.00 for 30 consecutive business days, putting it out of compliance with Nasdaq’s minimum bid price rule. The company has 180 days, until October 19, 2026, for its closing bid to reach at least $1.00 for 10 straight business days to regain compliance.
Medicus Pharma Ltd. reported that it sold a total of 4,471,038 common shares to YA II PN, Ltd. (Yorkville) under a previously disclosed Standby Equity Purchase Agreement. These unregistered sales, completed between December 19, 2025 and March 6, 2026, generated approximate aggregate consideration of $3,846,910.
The company has used part of the net proceeds to prepay a portion of an outstanding debenture held by Yorkville, reducing that obligation. The shares were issued in private transactions relying on the Section 4(a)(2) exemption from registration, and Yorkville may resell them under an effective registration statement while Medicus may request additional share purchases under the SEPA, subject to its conditions and limitations.
Medicus Pharma Ltd. entered into a new financing deal with YA II PN, Ltd. (Yorkville), issuing a debenture with a principal amount of $8,000,000. The company received approximately $5.7 million in net proceeds after using about $1.7 million to fully repay remaining debentures from a May 2025 financing and accounting for original issue discount and fees. The debenture carries 8.00% annual interest, which can increase to 18.00% if certain events of default occur, and matures on September 17, 2026. Medicus must make monthly payments of $650,000 plus accrued interest in cash starting 45 days after issuance, with any remaining balance due at maturity. All company subsidiaries entered into a global guaranty in favor of Yorkville, and the company may redeem the debenture early in cash, in whole or in part.